<![CDATA[지아이이노베이션 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=39949>Mon, 13 Apr 2026 12:43:43 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[지아이바이옴 ‘항암 마이크로바이옴 치료제 GB104’ 국내 임상 IND 승인]]>https://www.newswire.co.kr/newsRead.php?no=960922Mon, 06 Feb 2023 09:03:17 +0900<![CDATA[지아이이노베이션, 코스닥 상장 증권신고서 제출… 3월 상장 목표]]>https://www.newswire.co.kr/newsRead.php?no=960535Mon, 30 Jan 2023 17:58:41 +0900<![CDATA[지아이이노베이션, 2023 혁신형 제약기업으로 선정]]>https://www.newswire.co.kr/newsRead.php?no=960096Thu, 19 Jan 2023 15:04:16 +0900<![CDATA[GI Innovation Forms Co-representative System by Recruiting CEO Byung-Geon Rhee, Former CEO of GC Pharma and SCM Lifescience]]>https://www.newswire.co.kr/newsRead.php?no=940588Mon, 07 Mar 2022 10:16:13 +0900<![CDATA[GI Innovation and Cellkey to Develop Next-generation Innovative Immuno-oncology through Biomarker Joint Research]]>https://www.newswire.co.kr/newsRead.php?no=940133Fri, 25 Feb 2022 10:34:56 +0900